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Clinical Case Report
ABSTRACT
Secretory carcinoma of the breast (SBC) is a rare breast neoplasm. Most of the patients present at an early stage with a 
relatively indolent clinical course. Lymph node and distant metastasis are also very infrequent. The histomorphological 
features of the secretory breast carcinoma are quite characteristic. Predominantly three histological patterns, solid, 
microcystic, and tubular, have been noted with copious amounts of intra and extracellular secretory material. Most 
commonly, no positivity for estrogen receptor (ER), progesterone receptor (PR) and ERBB2(HER2/neu) is observed in 
SBCs. As SBC can occasionally be hormone receptor-positive, they should not be categorized in the triple-negative breast 
carcinoma (TNBC) group in general. A very characteristic genetic translocation t (12;15) has been noted in this rare tumor, 
resulting in a fusion between ETV6 and NTRK3 proteins. We present a case of a 60-year-old lady who presented with 
right breast lump of 1-month duration and was managed by lumpectomy and sentinel lymph node dissection. Axillary 
dissection was not performed because the sentinel lymph node biopsy was negative. Postoperative radiotherapy was 
given to the right breast with a boost to the tumor bed. No adjuvant chemotherapy was given No recurrence has been 
noted even after a year of the completion of treatment 
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INTRODUCTION
Secretory carcinoma of the breast (SBC) is a 
rare breast neoplasm. The overall incidence is less 
than 0.15% and was first described historically by Mc 
Divitt and Stewart1 in the year 1966, and they named 
it as juvenile breast carcinoma owing to the increased 
number of cases in the pediatric age group. However, 
it has been renamed after recognizing that this tumor 
may occur in a wide age range and also because of its 
characteristic histomorphological findings.1,2
Most of the patients present at an early stage 
with a relatively indolent clinical course. Lymph node 
metastasis is seen in 30% of individuals, and distant 
metastasis is also not frequent.2,3 The histomorphological 
features of the SBCs are quite characteristic and can be 
easily distinguishable from invasive duct carcinomas. 
Predominantly three histological patterns, (i) solid, 
(ii) microcystic, and (iii) tubular, have been noted with 
copious amounts of intra and extracellular secretory 
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material. Cellular atypia is usually minimal.4 Hormone 
receptor status is also very much characteristic in 
SBC. Most frequently, they do not show positivity for 
estrogen receptor (ER), progesterone receptor (PR) 
and ERBB2(HER2/neu). Therefore, SBCs very frequently 
show features of triple-negative breast carcinoma 
(TNBC). They also express cytokeratin 5/6, 14, 17, and 
c-Kit (CD117), which are also seen in the basal-like 
breast carcinomas (BLBC).5 Typically, 75–80% of the 
tumors classified as TNBCs belong to the basal-like 
breast cancer group, and they behave more aggressively 
and cause rapid vascular invasion.6 Transcriptomic 
analysis of breast malignancy revealed some distinctive 
genetic signatures, which is the basis for the intrinsic 
molecular subtyping of breast cancer. BLBC is one of 
the subtypes. It is defined by the expression of genes 
characteristic of the basally located epithelial layer 
of the mammary gland.7 BLBCs also uniformly lack 
molecular targets, which determine the responsiveness 
of highly effective targeted therapy.7,8 BLBCs share 
some features with SBCs in terms of expression of 
cytokeratin 5/6, 14, 17, and c-Kit (CD117).5 A recent 
study also highlights the heterogeneity within the 
TNBC group, both morphologically and prognostically. 
They also encompass certain tumors with a far better 
prognosis than the other members of this group.9 A 
very characteristic genetic translocation t (12;15) has 
been noted in this rare tumor, resulting in a fusion 
between E26 transformation-specific translocation 
variant 6 (ETV6) and neurotrophic receptor tyrosine 
kinase 3 (NTRK3) which creates a fusion protein ETV6-
NTRK3 resulting in activation of two oncogenic effector 
pathways.10
We present a case of a 60-year-old lady who 
presented with right breast lump of 6 months duration 
and was managed by lumpectomy and sentinel 
lymph node dissection and adjuvant radiotherapy. 
The radiological, histomorphological, and molecular 
features of SBC are also discussed.
CASE REPORT
A 60-year-old lady presented in the surgical 
outpatient clinic with the chief complaint of a palpable 
right breast lump over the last month. She had a 
fine needle aspiration cytology done at a local place, 
which showed malignancy. On examination, the mass 
appeared non-tender, firm, mobile, and was located in 
the central quadrant (Figure 1A). The lesion measured 
approximately 3x3 cm. No axillary lymph node was 
palpable at that time. The mammography showed a 
well-defined, sub-areolar, 3x2 cm radio-opaque lesion 
with no evidence of microcalcification. Two Giemsa 
stained aspiration smears undertaken during the 
consultation were also examined simultaneously. 
The smears were very cellular, with cells showing 
minimal nuclear atypia and arranged in cohesive clusters 
and sheets in a fluid background. No myoepithelial cells 
were detected. Based on those findings, the retro 
areolar mass was diagnosed as a malignant epithelial 
tumor (Figure 1B and 1C).
The patient was counseled about the disease 
status and the need for surgical intervention. A plan 
of lumpectomy with sentinel lymph node dissection 
was decided. The sentinel lymph node biopsy was 
performed, and the tissue was sent to the department 
of histopathology for an intraoperative frozen section. 
Grossly, a total of seven lymph nodes was identified 
in the whole sentinel lymph node specimen, and none 
of them showed metastatic deposit under microscopic 
examination. As the sentinel lymph nodes were free 
from metastasis, no axillary dissection was performed, 
and only the lumpectomy specimen was sent for final 
histopathological evaluation.
GROSS AND MICROSCOPIC FEATURES
The lumpectomy specimen measured 2.3x2.2 cm 
and was oriented with sutures. Adequate sections were 
taken and were examined under light microscopy. 
The tumor cells were arranged in tubules, micro 
cysts, and follicles. A focally solid growth pattern 
was also noted. Within the micro cysts, there were 
abundant, pink, eosinophilic secretions, which 
were intensely positive for Periodic acid Schiff (PAS) 
and also resistant to diastase. Intracytoplasmic 
vacuolation and eosinophilic secretions were also 
noted. Tumor cells were mitotically not very active, 
and nuclear pleomorphism was also not conspicuous 
(Figures 2A, 2B, 2C). All the resection margins were 
tumor-free (at least more than 10 mm away from the 
tumor). As a part of the routine evaluation of the breast 
specimen, hormone receptor study was also performed. 
Tumor cells were uniformly negative for estrogen (ER) 
and progesterone (PR) receptors. Evaluation for HER2/
neu was done by immunostain and incomplete; faint 
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membranous staining was noted in more than 10% of 
the tumor cells (Figures 2D, 3A, 3B). Hence, the tumor 
was labeled as negative (score 1) and fluorescent in-situ 
hybridization (FISH) was not performed.11 In addition 
to that, diffuse membranous and cytoplasmic positivity 
for cytokeratin 5/6 and S100-P were also documented 
in the index case (Figures 3C, 3D). Hence, we were 
dealing with a case of secretory breast carcinoma.
The FISH study was also performed from the 
paraffin-embedded sections to confirm the diagnosis. 
Dual-color break-apart probes (SureFISH®, Agilent, 
St.Clara, USA) were used for FISH evaluation of both 
ETV6 (12p13.2) and NTRK3 (15q25.3) gene. Fifty 
nuclei were counted, and red-green split signals were 
noted in 20 and 19 nuclei for ETV6 and NTRK3 gene, 
respectively (Table 1, Figure 4A, 4B). Therefore, the 
characteristic translocation was present in the index 
case. Subsequently, a diagnosis of secretory breast 
carcinoma was offered in this case. The patient has 
been kept in a close follow-up. No recurrence or 
Figure 1. Mammography and photomicrographs of the aspiration smears. A – Well defined, sub-areolar, radio-
opaque lesion within the breast; B – Cohesive clusters of tumor cells (Giemsa, 100X); C – Mildly pleomorphic 
polygonal tumor cells with centrally placed nuclei in a fluid background (Giemsa, 400X).
Table 1. Result of ETV6 and NTRK3 translocation analysis.
ETV6 translocation ETV6 (Orange/Green) 5’ ETV6 (Orange) 3’ ETV6 (Orange) No. of cells
Signals in cell 1 1 1 20/50
NTRK3 translocation NTRK3 (Orange/green) 5’NTRK3 (Orange) 3’ NTRK3 (Orange) No. of cells
Signal/s in cell 1 1 1 19/50
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metastasis was noted after a year of lumpectomy, 
which has been confirmed by a positron emission 
tomography (PET) scan.
DISCUSSION
SBC is a rare breast malignancy with an overall 
incidence of less than 0.15%. It was first reported as 
juvenile breast carcinoma.1 Afterward, it was shown 
that this tumor affects all age groups and can be 
detected in both males and females.12 According to 
Jacob et al.13 the mean age of SBC is 56 years.13 This 
tumor has an indolent clinical course, and according to 
Horowitz et al.2 the 5-year and 10-year cause-specific 
survival are 94.4% and 91.4%, respectively.14 The 
location of the tumor varies according to the age group. 
Adult patients present with upper outer quadrant 
mass, whereas in the young population, this is most 
commonly seen in the subareolar region. In the present 
case also, the tumor was located in the subareolar 
region which can be explained by the smaller relative 
size of the breast mound in younger patients deep to 
the nipple-areola complex.15-17
Mammographic findings of SBC closely mimic a 
fibroadenoma as this carcinoma appears as a solitary, 
discrete lesion with a well-delineated margin. Since 
this carcinoma is more common in young girls, 
mammography always has diagnostic limitations 
because of the denser and glandular elements in the 
young breast. Ultrasonography of SBC also mimics 
a fibroadenoma. Mostly a well-circumscribed, hypo 
to isoechoic mass with micro lobulation is noted on 
ultrasound. Therefore, radiological findings of SBC 
overlap with other benign fibro-epithelial lesions of 
Figure 2. Photomicrography of the tumor. A – Microcystic and follicular arrangement of the tumor cells with 
eosinophilic extracellular secretion (H&E, 100X); B – Intracellular vacuolation and eosinophilic secretion (H&E, 200X); 
C – Magenta colored secretion for Periodic acid Schiff stain (H&E, 100X); D – No positivity for ER immunostain 
(200X).
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Figure 3. Photomicrography of the tumor: A – No reactivity to PR (100X), B – negative reaction to HER2/neu 
(200X); C – Diffuse membranous and cytoplasmic positivity for cytokeratin 5/6 (400X); D – Diffuse membranous and 
cytoplasmic positivity for S100-P (400X).
Figure 4. Photomicrography of FISH analysis. A – FISH analysis by dual-color break apart ETV6 probe. One fusion 
signal (red/green/yellow; arrowed) and one split (rearrangement) signal in the nucleus (400X); B – FISH analysis by 
dual-color break apart NTRK3 probe. Two fusion signal (red/green/yellow; arrowed) and two splits (rearrangement) 
signal in the nucleus (100X).
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the breast. In the present case, the mammography 
also showed a well-defined, sub-areolar, radio-opaque 
lesion with no evidence of micro calcification.5
As mentioned previously, the SBCs are frequently 
non-reactive for hormone receptor analysis (ER, 
PR, HER2/neu) with strong and diffuse cytoplasmic 
positivity for S-100. Therefore, SBC commonly behaves 
as TNBC. Perineural and lymphovascular invasions 
are also extremely rare in SBC. Strong and diffuse 
cytoplasmic positivity for S-100 is a very common 
finding.18
The Characteristic genetic translocation (ETV6-
NTRK3) of SBCs creates a fusion gene that codes a 
chimeric tyrosine kinase, which subsequently activates 
Ras-Mek1 and PI3K-Akt pathways, resulting in 
increased transforming and mitogenic activity of the 
fibroblasts and ductal epithelial cells. The chimeric 
protein also contributes to the expression of mammary 
growth factor protein in SBC, which is the key protein 
causing secretory changes, and its expression in SBCs 
is also very unique.19,20
The NTRK gene fusion involving NTRK1, NTRK2, 
or NTRK3 is present in several tumors, like; congenital 
mesoblastic nephroma, infantile fibrosarcoma, 
mammary analog secretory carcinoma and many other 
tumors of different organs which make them susceptible 
to tyrosine kinase inhibitors (TKI).21 Larotrectinib and 
entrectinib are the first generations of TKIs. The efficacy 
of the larotrectinib was studied in three clinical trials. 
According to the published data of 55 patients, 
where one breast cancer patient was included, it 
showed an 80% overall response rate. Whereas the 
partial and complete response was 62% and 13%, 
respectively.22 Entrectonib was also tried on tumors 
harboring NTRK fusions. However, no breast tumor 
patient was included.23 Both the drugs were well 
tolerated with mild side effects. Therefore, they can be 
used in TRK-fusion positive cancers. So far, two types 
of resistance to first-generation TKIs are known. One is 
on target, and the other one is off-target resistance. 
Next-generation TKIs can overcome the resistance to 
first degree TKIs.21,22
The incidence of lymph node metastasis is 
seen in 30% of patients, and a negative sentinel 
lymph node biopsy is usually associated with a 
better prognosis. If the size of the tumor is less 
than 2 cm, then, the chance of metastasis is also 
low.24 Horowitz et al.2 reviewed the SEER database 
of 83 patients of SBC. According to that, 80% of 
the younger cohort (<30 years) were treated with a 
simple mastectomy, and only one patient received 
adjuvant radiation. Whereas 48.7% of the elderly 
patients (>30 years) were treated with lumpectomy, 
and 56% of the same cohort received radiation. 
Radiation therapy increases long term survival in 
SBC, just like other invasive breast malignancies.25 In 
our case, the affected individual is a 60-year-old 
lady treated with breast conservation surgery and 
radiotherapy. As SBC is a slowly progressing tumor 
with the very infrequent possibility of metastasis, 
response to chemotherapy is low.25 Herz et al.26 in his 
case study also showed non-responsiveness of SBCs 
to the adjuvant chemotherapy. Therefore, adjuvant 
chemotherapy was not considered for our patient. 
She is disease-free at 1 year of follow up.
CONCLUSION
Secretory breast carcinoma is an uncommon, 
triple-negative breast tumor with a favorable clinical 
course. Radiologically, this tumor closely mimics 
fibroadenoma and other benign breast lesions. 
The morphology and genetic translocation of this tumor 
are also quite characteristic. There are no consensus 
guideline recommendations for the treatment of SBCs. 
Due to the indolent and slow‐growing nature of this 
tumor, most recurrences are seen between 10‐20 years 
after the initial presentation. Therefore, all the patients 
irrespective of their age demand long term follow-up.
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